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Abstract
 
Pigment dispersion syndrome causes iris pigment release and often progresses to elevated in-
traocular pressure and pigmentary glaucoma (PG). Because melanin pigment can have adjuvant
 
like properties and because the 
 
Gpnmb
 
 gene, which contributes to pigment dispersion in DBA/2J
(D2) mice, is expressed in dendritic cells, we tested the hypothesis that ocular immune abnor-
malities participate in PG phenotypes. Strikingly, we show that D2 eyes exhibit defects of the
normally immunosuppressive ocular microenvironment including inability of aqueous humor
to inhibit T cell activation, failure to support anterior chamber (AC)-associated immune devi-
ation, and loss of ocular immune privilege. Histologic analysis demonstrates infiltration of in-
flammatory leukocytes into the AC and their accumulation within the iris, whereas clinical
indications of inflammation are typically very mild to undetectable. Importantly, some of these
abnormalities precede clinical indications of pigment dispersal, suggesting an early role in dis-
ease etiology. Using bone marrow chimeras, we show that lymphohematopoietic cell lineages
largely dictate the progression of pigment dispersion, the ability of the eye to support induction
of AC-associated immune deviation, and the integrity of the blood/ocular barrier. These re-
sults suggest previously unsuspected roles for bone marrow–derived cells and ocular immune
privilege in the pathogenesis of PG.
Key words: inﬂammation • immune tolerance • delayed hypersensitivity • anterior chamber • 
leukocytes
 
Introduction
 
Pigment dispersion syndrome (PDS)
 
* 
 
is characterized by
the deposition of abnormally liberated iris pigment within
the anterior chamber (AC) and aqueous humor (AqH)
drainage structures. PDS is medically important as it is very
common among both glaucoma patients and the general
population (a population screen of 654 Caucasians detected
PDS in 2.45% of this population, none were previously
aware of the condition; reference 1). Many cases (
 
 
 
35%)
progress to develop elevated intraocular pressure (IOP) and
pigmentary glaucoma (PG; 2–4). The molecular mecha-
nisms causing PDS and determining whether or not it
progresses to PG are not known. PDS demonstrates simple
inheritance in some families, but in others it is more com-
plex and appears sporadic (5, 6).
DBA/2J (D2) mice develop a form of PG with similari-
ties to human PDS (7). Iridial pigment dispersal in D2 mice
is first clinically evident at 5–6 mo. By 9–10 mo, iris depig-
mentation is pronounced and increased IOP is common,
resulting in AC enlargement and glaucoma (7). The depig-
menting iris disease of D2 mice is genetically separable into
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Abbreviations used in this paper: 
 
AC, anterior chamber; ACAID, AC-
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D2, DBA/2J mice; DH, delayed hypersensitivity; IOP, intraocular pressure;
IPD, iris pigment dispersion; ISA, iris stromal atrophy; PDS, pigment dis-
persion syndrome; PG, pigmentary glaucoma; SFM, serum-free medium.T
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two distinct phenotypes, iris pigment dispersion (IPD) and
iris stromal atrophy (ISA), which are caused by mutations
in the 
 
Gpnmb
 
 and 
 
Tyrp1
 
 genes, respectively (8, 9). TYRP1
is believed to participate in melanosomal melanin synthesis,
whereas GPNMB is less well characterized but also present
in melanosomes (10–12). Because pigment dispersion
caused by 
 
Gpnmb
 
 mutation has strong similarities to human
PDS, including a pattern of radial iris depigmentation con-
sidered a hallmark of human PDS, D2 mice provide a valu-
able resource for defining factors that may contribute to
human PG (7, 8, 13).
In addition to a melanosomal component to the D2 dis-
ease, several intriguing observations suggest that pigment
dispersal in D2 eyes might involve immune dysfunction.
Foremost of these is that 
 
Gpnmb
 
 is expressed in some types
of dendritic cells (14, 15), a potent professional APC nor-
mally resident in the iris (16, 17). Furthermore, TYRP1,
as well as melanin itself, have been identified as antigens
relevant to inflammatory eye disease (18, 19) and melanin
can also exhibit adjuvant-like properties (18, 20). Al-
though D2 mice with altered GPNMB and TYRP1 func-
tion could theoretically support aberrant immune reactions
through a number of different pathways, a role of the im-
mune system in D2 pigment dispersion has not previously
been addressed.
Here, we test the novel hypothesis that ocular immune
abnormalities contribute to the pathogenesis of pigment
dispersion in D2 mice. We present multiple lines of evi-
dence for compromised ocular immune privilege, which is
accompanied by a mild but chronic inflammatory response
in D2 eyes. Importantly, we show that the genotype of
bone marrow–derived cells in D2 mice determines the
presence or absence of the prominent pigment dispersion
associated with mutation of 
 
Gpnmb
 
 through mechanisms
related to ocular immune privilege. These results demon-
strate that cells of bone marrow origin pathogenically con-
tribute to abnormal pigment dispersion. By implication,
these data suggest that previously unsuspected immune ab-
normalities may amplify the level of pigment dispersion and
therefore increase the likelihood of PDS progression to PG
in humans.
 
Materials and Methods
 
Animal Husbandry.
 
Female D2, C57BL/6J (B6), and B6D2F1/J
(B6D2F1) mice were obtained from The Jackson Laboratory.
BALB/c (BALB) mice were obtained from The Schepens Eye
Research Institute’s animal breeding facility. D2 mice and D2
bone marrow chimeras used in studies of AqH and AC-associated
immune deviation (ACAID) induction were aged at The Jackson
Laboratory under previously described environmental conditions
(7, 8), and shipped to The Schepens Eye Research Institute for
experimentation. All animals were treated according to the
guidelines of the Association for Research in Vision and Oph-
thalmology for use of animals in research. All experimental proto-
cols were approved by the Animal Care and Use Committee of
The Schepens Eye Research Institute or The Jackson Laboratory.
Where appropriate, mice were anesthetized using intraperitoneal
 
injection of ketamine (Ketalar; Parke-Davis) and xylazine (Rom-
pun; Phoenix Pharmaceutical).
 
AqH Collection and Analysis.
 
AqH was collected, pooled (2
 
 
 
l/eye, 6–10 eyes/pool), and centrifuged at 4,000 rpm for 4 min
(21). Protein concentration was determined using 1 
 
 
 
l of the su-
pernatant (BCA; Pierce Chemical Co.), and the remaining super-
natant was frozen immediately at 
 
 
 
70
 
 
 
C until used in the T cell
proliferation assay. The sediment after centrifugation was resus-
pended in 20 
 
 
 
l PBS and 10 
 
 
 
l was used to count cells using a
hemocytometer. Remaining cells from each age group were
combined, stained with Giemsa, and subjected to differential
analysis. FACS
 
® 
 
profiles of AqH were collected by labeling the
pooled AqH of 10 eyes from 6-mo-old female D2 mice with
conjugated mAb.
 
Flow Cytometry.
 
The conjugated mAb used for FACS
 
® 
 
analy-
sis of AqH preparations were against murine MHC class II FITC
(M5/114; The Jackson Laboratory Flow Cytometry Service),
murine CD11b PE (BD Biosciences), and murine CD11c APC
(BD Biosciences). The mAbs used to analyze bone marrow chi-
meras were against murine MHC class I H-2K
 
d 
 
PE (SF1-1.1; BD
Biosciences) and murine H-2K
 
b 
 
FITC (28-13-3s; The Jackson
Laboratory Flow Cytometry Service). Labeling was assessed by
multicolor flow cytometry (FACScan™ or FACScalibur
 
®
 
; BD
Biosciences) and analyzed using the CellQuest 3.3 data reduction
system (BD Biosciences).
 
Anti-CD3 Stimulated Assay for In Vitro T Cell Proliferation.
 
T
cells were isolated from single cell suspensions of spleens from
naive BALB mice using a T cell enrichment column (R&D Sys-
tems). Enriched T cells were resuspended in serum-free me-
dium (SFM). Using a 96-well V-shaped bottom plate (Corn-
ing), 2.5 
 
  
 
10
 
4 
 
enriched T cells in 10 
 
 
 
l SFM and 5 
 
 
 
l AqH or
PBS were added per well and cultured for 1 h, followed by the
addition of 10 
 
 
 
l hamster anti–mouse CD3e IgG (2C11, 2.5
 
 
 
g/ml; BD Biosciences) in 10 
 
 
 
l SFM or 10 
 
 
 
l SFM alone.
Cells were pulsed with 2.5 
 
 
 
l 20 mCi/ml [
 
3
 
H]thymidine for the
final 8 h of the 48-h incubation (37
 
 
 
C, 5% CO
 
2
 
-95% hu-
midified air mixture) and [
 
3
 
H]thymidine incorporation mea-
sured in cpm.
 
Induction of OVA-specific ACAID.
 
OVA was injected (50 
 
 
 
g
in 2 
 
 
 
l HBSS) into the AC of one eye of mice. 7 d later, these
mice were immunized subcutaneously with 100 
 
 
 
g OVA emul-
sified 1:1 in CFA (total volume 100 
 
 
 
l). Positive control mice re-
ceived subcutaneous immunization without any previous expo-
sure to OVA. After another 7 d, 200 
 
 
 
g/10 
 
 
 
l OVA was injected
intradermally into one ear pinna, and swelling of the injected ear
was assessed 24 h later using an engineer’s micrometer (Mitutoyo
227-101). Negative controls received only intrapinnae injections
of OVA. Ear swelling is expressed as (24-h measurement of the
ear) 
 
  
 
(0-h measurement of the ear).
 
Intracameral Tumor Growth.
 
After making an incision at the
center of the cornea with the tip of a 30-G needle, 3 
 
 
 
l air was
injected into the AC, followed by 2 
 
 
 
l suspended CT26.WT
(10
 
4
 
) or T lymphoma L5178Y-R (2 
 
  
 
10
 
3
 
) cells. The remaining
1 
 
 
 
l air served to seal the incision. AC growth of tumors was
monitored using a slit-lamp biomicroscope (21).
 
Clinical and Histologic Analysis.
 
Eyes were examined with a
slit-lamp biomicroscope and photographed with a 40
 
  
 
objective
lens. Phenotypic assessment of iris atrophy, dispersed pigment,
and transillumination was performed according to previously de-
scribed criteria (7, 9). Fluorescein leakage studies used mice intra-
peritoneally injected with 25% sodium fluorescein at a dose of
0.01 ml per 5–6 g body weight (Akorn Inc.; reference 22). Histo-
logic analyses used hematoxylin and eosin–stained sections of eyesT
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fixed in phosphate-buffered glutaraldehyde paraformaldehyde
mixture (7, 9).
 
Generation and Analysis of Bone Marrow Chimeras.
 
Bone mar-
row chimeras were generated as follows: 4–8-wk-old female D2
and B6D2F1 mice were lethally irradiated (1,000 rad from a 
 
137
 
Cs
source) and then received 200 
 
 
 
l intravenous injections contain-
ing 5 
 
  
 
10
 
6 
 
T cell–depleted bone marrow cells from the indi-
cated donor strains. Donor marrow was depleted of T lympho-
cytes with 10 
 
 
 
g/ml purified mAbs to CD4 (GK1.5; The Jackson
Laboratory Flow Cytometry Service) and CD8a (53-6.72; The
Jackson Laboratory Flow Cytometry Service). Peripheral blood
extracted from the lateral tail vein of chimeras was assessed by
multicolor flow cytometry to determine the degree of chimerism.
Eyes of chimeras were assayed at 3–5-wk intervals.
 
Gene Abbreviations.
 
The official full names of genes (with
abbreviated protein designations used here in parentheses) are:
glycoprotein (transmembrane) nmb (GPNMB); tyrosinase-re-
lated protein 1 (TYRP1); transforming growth factor, beta
 
 
 
2
(TGF
 
 
 
2); tumor necrosis factor (ligand) superfamily, member 6
(CD95L); and tumor necrosis factor receptor superfamily,
member 6 (CD95).
 
Results
 
Compromised Ocular Immunosuppression: Altered Microenvi-
ronment.
 
Normal AqH is strongly immunosuppressive and
profoundly inhibits T cell activation in vitro (23). We
tested AqH from D2 and control BALB mice for capacity
to suppress anti-CD3–driven T cell proliferation in vitro
(Fig. 1). As expected, AqH from BALB eyes completely
suppressed T cell proliferation whereas D2 AqH never in-
hibited T cell proliferation and actually displayed mitogenic
activity, demonstrating the existence of a compromised in-
traocular immunosuppressive environment. Similar results
were obtained using BALB and D2 AqH at concentrations
of 3, 10, and 20%. AqH from D2 eyes lacked immunosup-
pressive properties at both 2 and 4 mo, ages that actually
precede clinically detectable pigment dispersion.
 
Compromised Ocular Immunosuppression: Deficient ACAID.
 
Ocular immune privilege expresses itself in part through a
form of eye-dependent tolerance termed ACAID (24). In-
jection of antigenic material into the AC of wild-type mice
induces a deviant systemic immune response that is devoid
of the effectors causing immunogenic inflammation: T cells
that mediate delayed hypersensitivity (DH) and B cells that
secrete complement-fixing antibodies. Thus, in contrast to
antigens injected subcutaneously, antigens injected into the
AC do not normally result in DH upon subsequent chal-
lenge with the same antigen, whether encountered in the
eye or elsewhere. When ocular immune privilege is com-
promised, the capacity to support ACAID is usually abol-
ished as well. Next, we examined whether eyes of aging
D2 mice were capable of supporting ACAID induction
(Fig. 2). As anticipated, OVA injected into the AC of con-
trol BALB eyes led to a profound impairment of OVA-spe-
cific DH (Fig. 2 A). OVA injected into the AC of 2-mo-old
D2 mice moderately impaired the development and ex-
pression of DH (Fig. 2 B), whereas injection of OVA into
AC of 4- or 6-mo-old D2 mice failed completely to inhibit
OVA-specific DH (Fig. 2, C and D). These results suggest
that a functional breakdown of conditions supporting im-
mune privilege exists in D2 eyes before the onset of clinical
disease.
 
Compromised Ocular Immunosuppression: Innate Immune
Privilege.
 
Although immunosuppressive properties of AqH
and the capacity to support ACAID induction are reliable
Figure 1. D2 AqH lacks immunosuppressive properties. T cells were
added to medium containing AqH at various concentrations, as shown
here for 20% AqH from BALB or D2 mice of the indicated ages. Cells
were stimulated with anti-CD3 antibodies for 48 h and assayed for
[3H]thymidine incorporation into proliferating cells. Single pools of AqH
were used for each age in the assay, each pool consisting of 6–10 eyes.
Values are mean cpm   SEM of three to six wells.
Figure 2. Deficient ACAID induction in D2 mice. ACAID induction
was assessed in aged cohorts of mice, as shown here for (A) 2-mo-old
BALB mice, (B) 2-mo-old D2 mice, (C) 4-mo-old D2 mice, or (D)
6-mo-old D2 mice. 50  g OVA was injected into the AC (OVA-AC). 1
wk later the mice were immunized subcutaneously with OVA plus CFA
and challenged with intrapinnae injections of OVA after an additional
7 d. DH responses are indicated by increased ear thickness 24 h after chal-
lenge. Positive controls (POS) received only immunizations of OVA plus
CFA injected subcutaneously, but no injections of OVA into AC. Nega-
tive controls (NEG) were naive mice receiving only intrapinnae chal-
lenges. Mean ear swelling responses   SEM (five mice per group) are
presented. *, values significantly lower than positive controls (P   0.05,
Student’s t test).T
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corollaries of ocular immune privilege, they do not test di-
rectly if immune privilege is present and intact. Our next
experiments evaluated whether ocular immune privilege is
retained in D2 mice as they acquire IPD.
Innate immune privilege can be tested by examining the
fate of mice receiving AC injections of syngeneic tumors.
TGF
 
 
 
2, a key immunomodulatory factor constitutively
present within AqH, blocks the ability of CD95L to trigger
neutrophil cytolytic activity and cytokine release in the
normal AC (25). Therefore, tumor cells expressing CD95L
that are implanted in the AC are not vulnerable to destruc-
tion by CD95
 
  
 
neutrophils and these recipients succumb to
progressive tumor growth and metastasis (26). By contrast,
when implanted into nonprivileged sites, CD95L
 
  
 
tumor
cells activate CD95
 
  
 
neutrophils and are rejected by these
innate immune effectors (the activated neutrophils), per-
mitting recipient survival. To assess the integrity of in-
nate ocular immune privilege in D2 mice at 2 and 7
mo,  CD95L
 
  
 
or CD95L
 
  
 
DBA/2-derived T lymphoma
L5178Y-R tumor cells were injected into the AC (Fig. 3
A). Regardless of age, D2 recipients of CD95L
 
  
 
tumor cells
developed progressively growing tumors and 100% of these
mice died by 18 d (not depicted). Similarly, 2-mo-old D2
recipients of CD95L
 
  
 
tumor cells succumbed to their tu-
mors, indicating that innate immune privilege was intact.
By contrast, a high proportion (
 
 
 
50%) of 7-mo-old D2
mice were able to contain the intraocular growth of
CD95L
 
  
 
tumor cells, and these mice survived. Thus, innate
immune privilege appears to be intact in eyes of 2-mo-old
D2 mice, but is compromised by 7 mo.
 
Compromised Ocular Immunosuppression: Adaptive Immune
Privilege.
 
Adaptive immune privilege can be tested by ex-
amining the fate of histoincompatible tumor cells injected
 
into the AC. Ocular immune privilege is revealed when
histoincompatible tumors grow progressively in the AC,
but are rejected when implanted subcutaneously (27). For
these experiments, CT26.WT, a chemically induced colon
carcinoma cell line derived from BALB mice, was selected
because this mouse strain shares with D2 the same 
 
H2
 
 hap-
lotype, 
 
H2
 
d
 
, but differs from D2 at multiple minor histo-
compatibility loci. CT26.WT tumor cells were injected ei-
ther into the AC or subcutaneous space (positive control
for rejection) of D2 mice at 2 and 7 mo. As negative con-
trols, CT26.WT cells were similarly injected into 2-mo-
old syngeneic BALB mice. CT26.WT cells never formed
tumors after injection into the subcutaneous space of D2
mice, although they readily formed tumors at this site in
BALB mice. This indicates that systemic immunity of D2
mice is capable of detecting and destroying histoincompati-
ble tumor cells placed at a nonimmune privileged site. By
contrast, CT26.WT cells formed progressively growing tu-
mors in the AC of 2-mo-old D2 (Fig. 3 B) and BALB
mice. Moreover, the rate of tumor growth was comparable
in both sets of recipients (not depicted). This indicates that
eyes of 2-mo-old D2 mice offer adaptive immune privilege
to histoincompatible tumor cells. However, CT26.WT tu-
mor cells that formed tumors in the eyes of 7-mo-old D2
mice exhibited a significant delay in the onset of tumor
growth compared with that observed in 2-mo-old D2 (Fig.
3 B). Because delayed outgrowth of histoincompatible tu-
mor cells is an expression of compromised immune privi-
lege, this result indicates adaptive immune privilege attenu-
ates in the eyes of older D2 mice. Importantly, our tumor
growth experiments show deficits in both adaptive and in-
nate immune privilege in 7-mo-old D2 mice, an age when
iris pigment dispersion is aggressive.
 
Compromised Ocular Immunosuppression: Deficient Blood/
Ocular Barrier.
 
An intact blood/ocular barrier is believed
to be an important component of normal ocular immune
privilege. Normal AqH contains extremely low levels of
protein and no leukocytes, indicating that barriers nor-
mally exclude virtually all plasma proteins and leukocytes
from entering the ocular microenvironment. AqH from
2-mo-old D2 eyes contained barely detectable amounts of
protein, similar to levels found in AqH of normal BALB
eyes. However, AqH from 4-mo-old D2 mice contained
slightly elevated levels of protein and these levels contin-
ued to rise through the ages tested (Fig. 4 A). No rise of
protein levels occurred in AqH from older BALB mice.
We first detected leukocytes in AqH of 6-mo-old D2
mice with higher numbers of inflammatory cells present
at 7 mo (Fig. 4 B). The predominant leukocyte present at
6 mo was the neutrophil whereas mononuclear cells pre-
dominated at 7 mo (Fig. 4 C). Ingested melanin was fre-
quently seen in the cytoplasm of these mononuclear cells.
FACS
 
® 
 
analysis of AqH at 6 mo revealed that the infiltrat-
ing leukocytes stained positive for CD11b, CD11c, and
MHC class II (including MHC class II
 
  
 
CD11b
 
  
 
CD11c
 
 
 
and MHC class II
 
  
 
CD11b
 
  
 
CD11c
 
  
 
phenotypes; not de-
picted). These phenotypes indicate that macrophages and
dendritic cells are present. AqH collected from 10-mo-
Figure 3. Compromised innate and adaptive immune privilege to in-
tracameral tumor cells in aged D2 mice. (A) CD95L  tumor cells were
injected into the AC of 2- and 7-mo-old D2 mice. Percentage of recipi-
ents surviving through 30 d are indicated. (B) CT26.WT tumor cells
were injected into the AC of 2- and 7-mo-old D2 mice. Percentage of
AC filled with tumor is indicated through 11 d after tumor injection. *, a
significant difference (P   0.05, Student’s t test).T
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old D2 mice contained even higher levels of protein but
very few leukocytes, suggesting that the intraocular in-
flammatory response had abated. Leukocytes were never
detected in AqH of BALB mice at any age. These results
strongly suggest that D2 mice experience breakdown of
the blood/ocular barrier at  4 mo, after which inflam-
matory leukocytes enter the AC. This inflammatory re-
sponse is sustained for several months, but declines as the
mice reach 10 mo. At no time during this interval did the
eyes of these mice become red or show evidence of se-
vere inflammation.
To directly assess the functional integrity of the blood/
ocular barrier in D2 mice, we performed fluorescein an-
giography on 2–7-mo-old mice. As expected, no evidence
of fluorescein vascular leakage from intraocular vessels was
observed in control BALB and B6 mice, and before 4 mo,
no fluorescein leakage occurred in eyes of D2 mice (Fig. 4
D). In D2 older than 4 mo, fluorescein leakage was ob-
served in some eyes, entering the AC from behind the iris
(Fig. 4 E) and from the iris stroma (Fig. 4 F). By 7 mo all
D2 eyes exhibited fluorescein leakage (n   10 of 10 eyes),
directly demonstrating that breakdown of the blood/ocular
barrier accompanies the pigment dispersion that results in
glaucoma in these mice.
Leukocyte Margination and Iris Infiltration. We examined
eyes from aging D2 mice for histologic indications of iris
infiltration by inflammatory cells. Through 3 mo, we de-
tected no inflammatory cells in the iris or AC of any D2
mice (Fig. 4 G). By 5 mo, however, and increasingly so by
7 mo, eyes of D2 mice demonstrated a mild but consistent
inflammatory response in the anterior segment. In 5- and
6-mo-old eyes, when clinical iris disease is barely detect-
able, mononuclear cells and neutrophils marginated along
the walls of iris vessels and were present both in the iris and
on the iris surface (Fig. 4 H). The number of these cells in-
creased through 7 mo, when pigment dispersion is ram-
pant, at which time macrophages were the most abundant
infiltrating leukocyte. In these older D2 mice, macrophages
containing melanin were present in the AC and accumu-
lated in the iris stroma, especially at the pupillary border
(Fig. 4 I) and in the trabecular meshwork. These data dem-
onstrate that leukocyte infiltration of the iris is an early fea-
ture of D2 pigment dispersion.
D2 Bone Marrow Is Necessary for Severe Pigment Dispersion
and Glaucomatous Progression. The D2 iris depigmentation
is initiated by a form of melanosomal toxicity with Gpnmb
mutation causing profound dispersal of pigment and Tyrp1
mutation causing iris stromal atrophy accompanied by mild
dispersal of pigment clumps into the AC (8, 9). Because D2
eyes have compromised immune privilege and the iris is in-
filtrated with leukocytes, we tested if bone marrow geno-
type affects the severity of pigment dispersion occurring in
eyes facing iris insults resulting from Gpnmb and Tyrp1 mu-
tation. Bone marrow contains progenitors for hematopoi-
etic lineages, causing reconstituted recipients to develop leu-
kocyte lineages with cells of the donor genotype. To test
Figure 4. Breakdown of
blood/ocular barrier integrity
and leukocyte infiltration of D2
eyes. AqH collected from D2
mice at indicated ages was ana-
lyzed for: (A) protein content,
(B) leukocyte content, and (C)
proportion of leukocytes that
were neutrophils and mononu-
clear cells. Values represent
mean   SEM of 10 mice. (D–F)
Fluorescein was injected intrave-
nously into D2 mice and the
presence of fluorescein within
and outside intraocular vessels
was assessed. The *indicate arti-
facts caused by light source re-
flections. (D) Before 4 mo, eyes
show only intravascular fluores-
cein (thin arrows). (E and F) Af-
ter 4 mo, eyes showed extravas-
cular fluorescein emerging from
behind the pupil (open arrow-
heads) and extravascular fluores-
cein diffusely staining the iris
stroma. (G–I) Histologic sections
of D2 eyes, revealing leukocyte
margination and iris infiltration.
(G) At 3 mo, D2 irides appear
normal and vessels lack leuko-
cyte margination (thin arrow). (H) At 5 mo and beyond, neutrophils (thick arrow) and macrophages (filled arrowhead) are present in the AC and on the
anterior surface of iris. H illustrates leukocyte margination (thick arrow) occurring in an iris vessel. (I) After 6 mo, the peripupillary border of the iris be-
comes thickened and is comprised of pigment-bearing macrophages (filled arrowhead) and neutrophils (thick arrow). Even in severely affected eyes such
as the one shown in I, iridial thickening is limited to the peripupillary margin. Original magnification:  630. UD, undetectable; NEUT, neutrophils;
MONO, mononuclear cells.T
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the effects of bone marrow genotype, we reconstituted D2
mice with B6D2F1 or D2 (control) marrow and followed
them clinically for indications of iris disease (Figs. 5 and 6).
Additionally, B6D2F1 mice were reconstituted with D2
marrow. B6D2F1 mice have wild-type iris morphology
and did not develop iris disease after reconstitution with
D2 marrow, indicating that the progeny of D2 bone mar-
row alone are not capable of causing the disease. As ex-
pected, lethally irradiated D2 recipients reconstituted with
D2 marrow developed transillumination defects (resulting
from iris depigmentation), severe pigment dispersion,
thickening of the pupillary border at 6 mo, and glaucoma-
tous AC enlargement. The severity and onset of these phe-
notypes were identical to unmanipulated D2 mice (7–9).
By contrast, D2 mice reconstituted with B6D2F1 marrow
exhibited significant reduction of iris depigmentation. The
rescuing effect of B6D2F1 marrow resulted in strikingly
less transillumination than in mice with D2 marrow at both
6 (compare Fig. 5 I with E) and 10 mo (compare Fig. 5 J
with F). These mice never developed the peripupillary iris
thickening typically observed in D2 at 6 mo. When ob-
served at 10 mo of age these recipients never developed se-
vere pigment dispersion characteristic of IPD (compare Fig.
6 I with F). Importantly, B6D2F1 marrow also prevented
the enlargement of the AC in D2 recipients at 10 mo
(compare Fig. 5 K with G). The AC normally becomes en-
larged due to elevated IOP in D2 mice at this age. The ab-
sence of AC enlargement shows that not only has the iris
disease been ameliorated in bone marrow–reconstituted
mice, but the glaucomatous progression toward PG has
been suppressed as well.
Despite the striking rescue of pigment dispersion and
peripupillary iris thickening associated with the D2-derived
GpnmbR150X mutation (8, 9), bone marrow genotype did
not affect all components of the D2 iris disease. D2 recon-
stituted with B6D2F1 marrow still displayed a small degree
of transillumination (Fig. 5, I and J) and iris stromal atrophy
(Fig. 6, H and I). In these mice, iris stromal atrophy that is
associated with the D2-derived Tyrp1b mutation appeared
to be unchanged.
Figure 5. B6D2F1 bone marrow suppresses depigmentation and AC enlargement. Representative eyes of bone marrow chimeras of indicated strains
and ages. Glaucoma in D2 mice is typically associated with a pigment-dispersing iris disease, resulting in changes to the morphology of the iris. Subse-
quently, dispersed pigment becomes aberrantly deposited on a variety of structures including the surface of the iris, lens, and cornea. Dispersed pigment is
also deposited in the AqH drainage structures, leading to increased IOP and enlargement of the AC (the space between the iris and cornea). The two left
columns show transilluminating views assaying the degree of iris depigmentation, detectable as red areas within the image where reflected light is passing
through the iris. The third and fourth columns show AC dimensions and representative FACS® profiles. (A–D) B6D2F1 recipients of D2 marrow show
no signs of depigmentation at any age and ACs of normal dimension with a closely juxtaposed cornea and iris (n   12 mice at 4 mo, 11 mice at 6 mo, and
8 mice at 10 mo). (E–H) D2 recipients of D2 marrow-developed iris disease and signs of glaucoma following a time course and severity indistinguishable
from unmanipulated D2 mice. These eyes developed moderate to severe iris transillumination and very enlarged ACs typical of mice with increased IOP.
Reconstitution is presumed based on the survival of the mice after lethal irradiation (n   12 mice at 4 mo, 12 mice at 6 mo, and 8 mice at 10 mo). (I–L)
Iris disease in D2 recipients of B6D2F1 marrow was significantly suppressed at all ages, as shown by relatively mild degrees of transillumination and ACs
of normal dimension (n   12 mice at 4 mo, 11 mice at 6 mo, and 9 mice at 10 mo).T
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B6D2F1 Bone Marrow Restores ACAID and Integrity of the
Blood/Ocular Barrier. To further characterize the rescuing
effect of B6D2F1 bone marrow on D2 recipients, a cohort
of these chimeric mice was analyzed at 6 mo for immune
status of the ocular microenvironment and immune privi-
lege. In addition to alleviating pigment dispersion, there
was little indication of the type and extent of inflammation
typically observed in eyes of D2 mice. AqH from chimeric
D2 recipients of B6D2F1 bone marrow contained no leu-
kocytes and barely detectable amounts of protein, revealing
that the blood/ocular barrier was intact. Moreover, the
eyes of the chimeric mice readily supported ACAID induc-
tion (Fig. 7 A). However, not all of the ocular immune ab-
normalities observed in D2 mice were corrected. AqH
from chimeric D2 mice reconstituted with B6D2F1 bone
marrow failed to suppress anti-CD3–driven T cell prolifer-
ation in vitro (Fig. 7 B).
Discussion
Our current experiments document fundamental new
aspects of pigment dispersion in D2 mice. We show that
D2 eyes destined to develop pigment dispersion and PG
have multiple abnormalities related to ocular immune priv-
ilege. AqH from affected D2 mice contains elevated pro-
tein levels and their iris vessels leaked fluorescein dye, indi-
cating a breakdown in the blood/ocular barrier. AqH from
D2 eyes also contained leukocytes (initially predominated
by neutrophils, then mononuclear cells) reflecting the mild
but sustained inflammation of the iris detected by histologic
study. Both innate and adaptive immune privilege were
compromised in eyes of 7-mo-old D2 mice tested with ap-
propriate challenges of tumor cells. This array of findings
implicates immune aberrations and inflammation in the
pathogenesis of pigment dispersion in D2 mice.
Although the above results suggest participation of im-
mune and inflammatory factors in the pathogenesis of pig-
ment dispersion in D2 mice, they do not address whether
they are primary disease characteristics or secondary conse-
quences of pigment dispersion. Melanin pigment has po-
tent adjuvant-like properties (20) and enhances intraocular
inflammation in experimental autoimmune uveitis (18).
Furthermore, melanosomal proteins are themselves po-
tently immunogenic (28, 29). Thus, it seemed reasonable
that dispersed pigment could contribute to a loss of ocular
immune privilege in D2 mice. Contradicting this idea, we
found that some of the immune abnormalities (lack of im-
munosuppressive properties of AqH at 2 mo and altered
ACAID induction at 2 and 4 mo) substantially precede pig-
ment dispersion. Further evidence against this idea is pro-
vided by our bone marrow chimera experiments. These
experiments show that reconstitution of irradiated D2 mice
with B6D2F1 marrow rescues the prominent pigment dis-
persion phenotype (IPD) that is caused by Gpnmb muta-
tion. However, bone marrow reconstitution did not rescue
the iris stromal atrophy phenotype caused by Tyrp1 muta-
Figure 6. B6D2F1 bone marrow
suppresses peripupillary thickening
and severe pigment dispersion. Eyes
of bone marrow chimeras of indi-
cated strains and ages. Representa-
tive eyes from each cohort and age
are shown, the number of mice per
cohort are the same as for Fig. 5. All
images are from clinical slit-lamp ex-
amination with broad beam illumi-
nation to assay for the presence of
dispersed pigment within the AC
and iris stromal morphology. (A–C)
B6D2F1 recipients of D2 marrow
maintain normal iris morphology at
all ages. (D–F) Eyes from D2 recipi-
ents of D2 marrow exhibit a charac-
teristic disease progression. At 4 mo,
irides exhibit predisease morphol-
ogy, 6-mo irides develop a signifi-
cant thickening surrounding the pu-
pil (arrowheads), and 10-mo irides
become severely atrophic. Dis-
persed pigment is visible on the lens
and AC structures (arrows) and iris
atrophy is pronounced, particularly
in the peripupillary margin. (G–I)
Eyes from D2 recipients of B6D2F1
marrow are characterized by a less
severe phenotype. At 4 mo, irides
show no signs of disease, at 6-mo iri-
des lack the pronounced peripupil-
lary thickening characteristic of un-
manipulated D2 eyes, and 10-mo irides maintain significant overall integrity and lack the presence of large amounts of dispersed pigment typically
observed on the lens, cornea, and iris. The peripupillary margin of 6- and 10-mo irides is mildly atrophic.T
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tion. Thus, low levels of clinically detectable, liberated pig-
ment persist in the eyes of the bone marrow chimeras. De-
spite the low level of liberated pigment, these chimeras are
rescued with respect to: (a) integrity of the blood/ocular
barrier, (b) leukocyte infiltration into the AqH, and (c)
ability to induce ACAID. This argues that the suppressible
immune ocular abnormalities detectable early in the disease
are not secondary to pigment dispersion.
The results of our radiation bone marrow chimera ex-
periments establish a causal relationship between the docu-
mented immune and inflammatory factors and the patho-
genesis of pigment dispersion in D2 mice. Irradiated D2
mice reconstituted with B6D2F1 bone marrow cells failed
to develop the full range and severity of pigment disper-
sion characteristic of unmanipulated D2 mice or irradiated
D2 mice reconstituted with D2 bone marrow. D2 mice
reconstituted with B6D2F1 marrow showed significantly
less pigment dispersion, iris transillumination, and peripu-
pillary swelling. Bone marrow contains progenitors of the
immune system that can account for the correction of the
immune abnormalities in the bone marrow chimeras.
There is no evidence that bone marrow–derived lineages
could directly rescue an inherent defect in pigmented cells
of the iris. Therefore, the prominent rescue of iris disease
observed in D2 recipients of B6D2F1 bone marrow indi-
cates that some component(s) of the suppressible immune
ocular abnormalities is directly pathogenic. Given the doc-
umented expression of Gpnmb in some types of dendritic
cells (14, 15) and the dependency of ACAID on cells posi-
tive for F4/80 (predominantly dendritic cells and mac-
rophages; 17, 30–32), we hypothesize that the prominent
pigment dispersion rescued here by bone marrow reconsti-
tution might be a consequence of lack of GPNMB func-
tion in D2 dendritic cells that have the GpnmbR150X muta-
tion. Future experiments will directly test this hypothesis.
There are also components of the D2 ocular disease that
appear to be insensitive to the genotype of bone marrow–
derived lineages. First, the D2 mice reconstituted with
B6D2F1 bone marrow maintained a degree of transillumi-
nation and iris atrophy indicative of the iris stromal atrophy
phenotype that is caused by mutation of Tyrp1. In contrast
to GPNMB, TYRP1 is thought to be melanocyte specific
(10, 33) and has not been documented in bone marrow–
derived lineages of the immune system. Second, the AqH
of D2 mice reconstituted with B6D2F1 bone marrow re-
mained incapable of suppressing T cell activation in vitro.
This may result from either the small percentage of residual
parental D2 bone marrow–derived cells in these mice, or
may reflect the consequence of a nonbone marrow–derived
ocular cell type that remains mutant in the eyes of these
chimeras (possibly iris pigment epithelial cells that normally
secrete factors that inhibit T cell proliferation). In either
case, the rescue of the IPD phenotype despite the contin-
ued inability of AqH to suppress T cell proliferation indi-
cates that this inability is not sufficient to induce the prom-
inent pigment dispersion associated with IPD.
The factors causing human PDS and conspiring to deter-
mine whether or not it progresses to elevated IOP and PG
are unknown. The pigment dispersion phenotype in D2
mice involves melanosomes, the specialized organelles of
melanin pigment production containing both TYRP1 and
GPNMB. Our previous studies suggest that mutations in
Tyrp1 and Gpnmb allow cytotoxic by-products of melanin
synthesis to leave melanosomes in abnormally high quanti-
ties, resulting in melanocyte insult, cell injury, depigmenta-
tion, and iris atrophy (8, 9). Importantly, the current studies
clearly demonstrate that the genotype of bone marrow–
derived cells determines the level of pigment dispersion as-
sociated with these melanosomal insults in otherwise iden-
tical eyes. Thus, multiple hits can synergize to either cause
or exacerbate the severity of the prominent pigment dis-
persion phenotype, IPD. One hit arises from a melanocyte
insult predisposing toward pigment release, which in D2
mice results from a genetically determined melanosomal
defect. Another hit arises from the immune system and de-
termines the overall level of depigmentation and course of
progression. Our finding that enlargement of the AC was
curtailed in D2 mice reconstituted with B6D2F1 bone
marrow further suggests that multiple hits are necessary for
progression of the disease to PG.
Synergistic interactions between melanosomal defects
and the immune system may also contribute to iris pigment
dispersion in human PDS and may explain the complex
pattern of occurrence in many families. Roles of melano-
some-derived insults, immune abnormalities, and bone
marrow–derived cells in human PDS are not defined. Ul-
Figure 7. B6D2F1 bone marrow restores ACAID induction but not
AqH immunosuppressive properties. (A) In contrast to unmanipulated
D2 mice, 6-mo-old D2 mice reconstituted with B6D2F1 marrow
(B6D2F1→D2) have a normal capacity to induce ACAID (compare with
Fig. 2). Mean ear swelling responses   SEM (five mice per group) are
presented. *, values significantly lower than positive controls (P   0.05,
Student’s t test). (B) Similar to unmanipulated D2 mice, 6-mo-old D2
mice reconstituted with B6D2F1 marrow also contain AqH lacking im-
munosuppressive properties (compare with Fig. 1). T cells were added to
medium containing 20% AqH, stimulated with anti-CD3 antibodies for
48 h, and assayed for [3H]thymidine incorporation. Values are mean
cpm   SEM of three to six wells.T
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trastructurally, abnormal melanosomes are present in the
iris of some human PDS patients (34, 35). Similar melano-
some abnormalities exist in D2 mice as young as 5 d after
birth and are present in the iris (36 and unpublished data).
This suggests that melanosomal disturbances might be in-
volved in both the human and mouse diseases. Importantly,
the form of inflammation observed in D2 eyes is mild,
lacking redness and severe inflammation. If present in hu-
man PDS, a similarly mild inflammatory response might be
subclinical on routine examination. Pigment-laden macro-
phages are present in the eyes of some human PDS/PG pa-
tients (35, 37, 38). Our current studies suggest that these
cells and other bone marrow–derived lineages should not
be excluded as active participants in the disease.
In conclusion, we present evidence for immune aberra-
tions and sustained, mild inflammation in eyes of D2 mice
and propose that a similar, and previously unsuspected, set
of abnormalities may occur in human PDS/PG. PG is a
relatively early onset and difficult to treat form of glau-
coma. Our studies suggest that developing treatments to
decrease the amount of dispersed pigment and/or reduce
inflammatory responses might be beneficial as new thera-
pies to prevent progression to glaucoma.
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